← Back to all trials
Not Yet Recruiting
NCT07792408
Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sex: Female
Ages: 18 Years – 50 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 148
Sponsor: Vertex Pharmaceuticals Incorporated
Summary
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.
Eligibility Criteria
Key Inclusion Criteria:
* Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m\^2), inclusive
* A total body weight of greater than (\>) 50 kg
Key Exclusion Criteria:
* History of febrile illness within 5 days before the first dose of study drug
* Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of study drug
Other protocol defined Inclusion/Exclusion criteria will apply.
Source: ClinicalTrials.gov (NCT07792408). StuddyBuddy aggregates publicly available trial information.
